Albireo Pharma Inc Stock News

Metropolitan Life Insurance Co NY boosted its holdings in shares of Albireo Pharma, Inc. (NASDAQ:ALBO) by 90,960.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,553 shares of the biopharmaceutical companys stock after acquiring an additional 4,548 shares during []

Albireo developed Odevixibat - a product as a pipeline - as a life-saving therapy for multiple ultra-rare pediatric liver disease indications.

Shares of Albireo Pharma, Inc. (NASDAQ:ALBO) have been given a consensus recommendation of Buy by the six research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1 year price target among []

Albireo Pharma, Inc. (NASDAQ:ALBO) shares reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $27.16 and last traded at $27.32, with a volume of 784 shares changing hands. The stock had previously closed at $27.75. A number of equities research analysts recently commented on ALBO shares. Zacks []

Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q3 2021 Results - Earnings Call Transcript

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -333.33% and -83.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

— Conference call and webcast to be held at 10:00 a.m. ET — — Conference call and webcast to be held at 10:00 a.m. ET —

– Seven abstracts accepted highlighting data in pediatric cholestatic and viral liver diseases –

– Agreement to accelerate commercialization of Bylvay™ (odevixibat) in Japan, a significant market for PFIC, Alagille syndrome and biliary atresia –

BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Networ

– Listed on the German national price list and all pharmacy software programs –

BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement st

– Bylvay now approved in U.S., EU and UK as first drug treatment for patients with PFIC –

Albireo Pharma Inc (NASDAQ: ALBO) has agreed to sell its Priority Review Voucher (PRV) for $105 million.  The FDA granted the PRV for Bylvay to treat pruritus in all types of progressive familial